Key Takeaways JNJ expects stronger 2025 growth, driven by new drug launches and expansion in Innovative Medicine. MRK remains dependent on Keytruda, raising concerns ahead of its 2028 loss of exclusivity. JNJ forecasts higher sales in second-half 2025 and projects 2025 as a catalyst year for future growth.Both Johnson & Johnson (JNJ) and Merck (MRK) are leading U.S. healthcare conglomerates — blue-chip pharmaceutical companies with massive R&D budgets and blockbuster drug portfolios.Both companies have a ...